| SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ, Lenka BABIČKOVÁ, Bohdan KADLEC, Yvona GRYGARKOVÁ, Jiří BARTOŠ, Jan CHALUPA, Tomáš TŘASOŇ, Jiří GRUNA, Jana ŠVECOVÁ a Helena COUPKOVÁ. Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population. In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. ISSN 1556-0864. 2011. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{946858,
author = {Skřičková, Jana and Keilová, Jana and Janasková, Tereza and Kolek, Vítězslav and Tomíšková, Marcela and Babičková, Lenka and Kadlec, Bohdan and Grygarková, Yvona and Bartoš, Jiří and Chalupa, Jan and Třasoň, Tomáš and Gruna, Jiří and Švecová, Jana and Coupková, Helena},
booktitle = {Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer},
keywords = {vinorelbin; Advanced NSCLC; First line treatment},
language = {eng},
title = {Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population},
year = {2011}
}
TY - CONF
ID - 946858
AU - Skřičková, Jana - Keilová, Jana - Janasková, Tereza - Kolek, Vítězslav - Tomíšková, Marcela - Babičková, Lenka - Kadlec, Bohdan - Grygarková, Yvona - Bartoš, Jiří - Chalupa, Jan - Třasoň, Tomáš - Gruna, Jiří - Švecová, Jana - Coupková, Helena
PY - 2011
TI - Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population
KW - vinorelbin
KW - Advanced NSCLC
KW - First line treatment
N2 - Lung cancer is the leading cause of cancer mortality in the Czech Republic. Approximately 80% of cases are NSCLC and 65% of patients have advanced disease at the time of diagnosis. For patients with advanced NSCLC and preserved functional status, the standard therapy is a double agent platinum-based chemotherapy. Most patients who receive first-line chemotherapy experience disease progression within 3 to 6 months of initiating therapy and the median survival time observed is 8 to 10 months. In this situation, there is a need to find effective therapeutic regimen with an administration as simple as possible and the most favorable toxicity profile. The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with NVBiv and NVBo.
ER -
SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ, Lenka BABIČKOVÁ, Bohdan KADLEC, Yvona GRYGARKOVÁ, Jiří BARTOŠ, Jan CHALUPA, Tomáš TŘASOŇ, Jiří GRUNA, Jana ŠVECOVÁ a Helena COUPKOVÁ. Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population. In \textit{Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer}. ISSN~1556-0864. 2011.
|
